الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Paradigm Therapeutics, Inc. annonce l'inscription du premier patient dans un essai de phase 3 pour le SD-101 (Zorblesia™) dans l'épidermolyse bulleuse

نشره PR Newswire · الولايات المتحدة منذ 1 س

Le SD-101 (Zorblesia™) est le premier traitement topique développé pour traiter les plaies et les lésions sur toute la surface de la peau chez les patients atteints des trois…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Associated Press (Business)

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Business Wire

Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy

Dow Jones Newswires

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires

Paradigm Therapeutics, Inc. annonce l'inscription du premier patient dans un essai de phase 3 pour le SD-101 (Zorblesia™) dans l'épidermolyse bulleuse

مشاركة

يستحق القراءة أيضًا

The Ford Foundation, one of the world’s largest grantmakers, will throw more weight behind democracy

Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy

Advancing Government Intelligence: Insights From the Data and Intelligence Training Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows